This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Beijing Tide Pharmaceutical Co., Ltd.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Cheung Ling Cheng: Innovator in ATR Kinase Inhibition
Introduction
Cheung Ling Cheng is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target ATR kinase-mediated diseases. His innovative work has the potential to impact the treatment of various proliferative diseases, including cancer.
Latest Patents
Cheung Ling Cheng holds a patent for a pyrazolopyrimidine compound used as an ATR kinase inhibitor. This compound, described by a general formula (I), is disclosed for its application in treating diseases mediated by ATR kinase. The patent also includes a preparation method for the compound, a pharmaceutical composition, and its use in therapeutic applications.
Career Highlights
Cheng is associated with Beijing Tide Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to innovation and a focus on addressing critical health challenges through effective pharmaceutical solutions.
Collaborations
Cheng collaborates with notable colleagues, including Yanping Zhao and Hongjun Wang, who contribute to his research endeavors. Their combined expertise enhances the potential for groundbreaking discoveries in the field of medicine.
Conclusion
Cheung Ling Cheng's contributions to the development of ATR kinase inhibitors exemplify the vital role of inventors in advancing medical science. His work not only showcases his innovative spirit but also holds promise for improving treatment options for patients with proliferative diseases.